Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Revuforj is typically indicated for the treatment of patients with specific type···【more】
Release date：2026-01-28Recommended：113
On June 24, 2025, Syndax Pharmaceuticals announced that the U.S. Food and Drug A···【more】
Release date：2026-01-28Recommended：103
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy originating from ···【more】
Release date：2026-01-28Recommended：86
Recently, Syndax Pharmaceuticals announced additional positive data from the AUG···【more】
Release date：2026-01-28Recommended：85
Lorlatinib is a third-generation ALK/ROS1 tyrosine kinase inhibitor, primarily i···【more】
Release date：2026-01-27Recommended：102
Lorlatinib is a third-generation targeted therapy indicated for ALK-positive met···【more】
Release date：2026-01-26Recommended：79
Concurrent use of this medicine with any of the following medications is general···【more】
Release date：2026-01-26Recommended：114
While certain medications should not be used together at all, in other cases, it···【more】
Release date：2026-01-26Recommended：103
While exerting the intended therapeutic effects, a medication may also induce ce···【more】
Release date：2026-01-26Recommended：106
In addition to the intended effects, medications may cause some adverse reaction···【more】
Release date：2026-01-26Recommended：103
Lorlatinib is an antineoplastic (anticancer) medication. It interferes with the ···【more】
Release date：2026-01-26Recommended：99
Lorlatinib is indicated for the treatment of patients with metastatic non-small ···【more】
Release date：2026-01-26Recommended：112
